IAMA Therapeutics Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$16.5M
- Investors
-
4
IAMA Therapeutics General Information
Description
Developer of a neuroscience drug discovery platform designed to provide personalized treatments for patients suffering from untreatable neurological conditions. The company's platform can significantly alleviate the learning and memory difficulties typical of patients with Down syndrome as well as the more significant behavioral manifestations of the autism spectrum, enabling patients to get treatment for their disorders.
Contact Information
Website
www.iamatherapeutics.comCorporate Office
- Via Filippo Turati, 2
- 16128 Genoa
- Italy
Corporate Office
- Via Filippo Turati, 2
- 16128 Genoa
- Italy
IAMA Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC (Series B) | 16-Apr-2025 | $16.5M | Completed | Clinical Trials - Phase 1 | ||
| 1. Early Stage VC (Series A) | 29-Mar-2022 | Completed | Pre-Clinical Trials |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
IAMA Therapeutics Patents
IAMA Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025257786-A1 | Benzoimidazole derivatives as nkcc1 inhibitors | Pending | 13-Jun-2024 | ||
| EP-4836783-A1 | Modulators of intracellular chloride concentration | Pending | 04-Jan-2024 | ||
| WO-2025146650-A1 | Modulators of intracellular chloride concentration | Inactive | 04-Jan-2024 | ||
| AU-2024258174-A1 | Process for the preparation of sulfamoylbenzoic acid derivatives | Pending | 18-Apr-2023 | ||
| EP-4698512-A1 | Process for the preparation of sulfamoylbenzoic acid derivatives | Pending | 18-Apr-2023 | C07C303/40 |
IAMA Therapeutics Signals
IAMA Therapeutics Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Indaco Venture Partners | Venture Capital | Minority | ||
| Tech and Biomedical Foundation | Venture Capital | Minority | ||
| CDP Venture Capital (Rome) | Venture Capital | Minority | ||
| Claris Ventures | Venture Capital | Minority |
IAMA Therapeutics FAQs
-
When was IAMA Therapeutics founded?
IAMA Therapeutics was founded in 2021.
-
Where is IAMA Therapeutics headquartered?
IAMA Therapeutics is headquartered in Genoa, Italy.
-
What is the size of IAMA Therapeutics?
IAMA Therapeutics has 10 total employees.
-
What industry is IAMA Therapeutics in?
IAMA Therapeutics’s primary industry is Drug Discovery.
-
Is IAMA Therapeutics a private or public company?
IAMA Therapeutics is a Private company.
-
What is IAMA Therapeutics’s current revenue?
The current revenue for IAMA Therapeutics is .
-
How much funding has IAMA Therapeutics raised over time?
IAMA Therapeutics has raised $25.3M.
-
Who are IAMA Therapeutics’s investors?
Indaco Venture Partners, Tech and Biomedical Foundation, CDP Venture Capital (Rome), and Claris Ventures have invested in IAMA Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process